Robust Immune Responses for Herpes Zoster Subunit Vaccine

Humoral response seen for 97.8% of HZ/su vaccine recipients versus 2% of placebo.
Humoral response seen for 97.8% of HZ/su vaccine recipients versus 2% of placebo.

HealthDay News — Recipients of the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, develop robust immune responses, according to a study published in the June 1 issue of The Journal of Infectious Diseases.

Anthony L. Cunningham, MD, from the University of Sydney, and colleagues presented immunogenicity results from 2 trials involving patients aged 50 years or older and aged 70 years or older who received 2 doses of HZ/su or placebo 2 months apart. In subcohorts with 3,293 and 466 participants for humoral and cell-mediated immunogenicity, respectively, serum anti-gE antibodies and CD4 T-cells expressing 2 or more of 4 activation  markers assessed after stimulation with gE-peptides were measured. 

Related Articles

The researchers identified a humoral response in 97.8 and 2% of HZ/su and placebo recipients, respectively, after vaccination. At 1 and 36 months post-dose 2, geometric mean anti-gE antibody concentrations increased 39.1- and 8.3-fold, respectively, over baseline in HZ/su recipients. In 93.3 and 0% of HZ/su and placebo recipients, respectively, there was a gE-specific CD42+ T-cell response. In HZ/su recipients, median CD42+ T-cell frequencies increased 24.6- and 7.9-fold over baseline at one and 36 months, respectively; in all age groups, the frequency remained ≥5.6-fold above baseline at 36 months. In all age groups there was an increase in the proportion of CD4 T-cells expressing all four activation markers over time.

"Most HZ/su recipients developed robust immune responses persisting for three years following vaccination," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline Biologicals SA, which funded the study.

Abstract/Full Text